[go: up one dir, main page]

PE20041078A1 - INHIBITING HETEROCYCLIC DERIVATIVES OF HUMAN LEUKOCYTIC ELASTASE (HLE) - Google Patents

INHIBITING HETEROCYCLIC DERIVATIVES OF HUMAN LEUKOCYTIC ELASTASE (HLE)

Info

Publication number
PE20041078A1
PE20041078A1 PE2003000910A PE2003000910A PE20041078A1 PE 20041078 A1 PE20041078 A1 PE 20041078A1 PE 2003000910 A PE2003000910 A PE 2003000910A PE 2003000910 A PE2003000910 A PE 2003000910A PE 20041078 A1 PE20041078 A1 PE 20041078A1
Authority
PE
Peru
Prior art keywords
cyanophenyl
tetrahydro
oxo
trifluoromethyl
phenyl
Prior art date
Application number
PE2003000910A
Other languages
Spanish (es)
Inventor
Karl-Heinz Schlemmer
Jorg Keldenich
Kevin Nash
Barbara Albrecht
Volkhart Li
Leila Telan
Mary F Fitzgerald
Dirk Meurer
Swen Allerheiligen
Lars Barfacker
Heike Gielen
Ulrich Rosentreter
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0220962A external-priority patent/GB0220962D0/en
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of PE20041078A1 publication Critical patent/PE20041078A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/20—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D239/22—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

SE REFIERE A UN COMPUESTO DE FORMULA I DONDE A ES UN ANILLO ARILO O HETEROARILO; R1, R2 Y R3 SON CADA UNO H, HALOGENO, NITRO, ENTRE OTROS; R4 ES TRIFLUOROMETILCARBONILO, HIDROXICARBONILO, HETEROARILO, ENTRE OTROS; R5 ES ALQUILO C1-C4 SUSTITUIDO O NO, AMINO; R6 ES H, FORMILO, AMINOCARBONILO, ENTRE OTROS; R7 ES HALOGENO, CIANO, ALQUILO C1-C6, ENTRE OTROS; Y1, Y2, Y3, Y4 E Y5 SON CADA UNO CH, N, CUYOS ANILLOS PUEDEN CONTENER 0-2 ATOMOS DE N. SON COMPUESTOS PREFERIDOS: ETIL 4-(4-CIANOFENIL)-6-METIL-2-OXO-1-[3-(TRIFLUOROMETIL)FENIL]-1,2,3,4-TETRAHIDRO-5-PIRIMIDINCARBOXILATO; (1S)-2-METOXI-1-METIL 2-OXOETIL 4-(4-CIANOFENIL)-6-METIL-2-OXO-1-[3-(TRIFLUOROMETIL)FENIL]-1,2,3,4-TETRAHIDRO-5-PIRIMIDINCARBOXILATO Y ETIL 6-(BROMOMETIL)-4-(4-CIANOFENIL)-2-OXO-1-[3-(TRIFLUOROMETIL)FENIL]-1,2,3,4-TETRAHIDRO-5-PIRIMIDINCARBOXILATO. SE REFIERE TAMBIEN A UNA FORMULACION FARMACEUTICA UTIL EN EL TRATAMIENTO DE EPOC, SINDROME CORONARIO AGUDO, INSUFICIENCIA CARDIACA POR INIHIBICION DE LA ELASTASA NEUTROFILICA HUMANA (ENH)REFERS TO A COMPOUND OF FORMULA I WHERE A IS AN ARYL OR HETEROARYL RING; R1, R2 AND R3 ARE EACH H, HALOGEN, NITRO, AMONG OTHERS; R4 IS TRIFLUOROMETHYLCARBONYL, HYDROXYCARBONYL, HETEROARYL, AMONG OTHERS; R5 IS C1-C4 ALKYL, SUBSTITUTED OR NOT, AMINO; R6 IS H, FORMYL, AMINO CARBONYL, AMONG OTHERS; R7 IS HALOGEN, CYANE, C1-C6 ALKYL, AMONG OTHERS; Y1, Y2, Y3, Y4 AND Y5 ARE EACH CH, N, WHOSE RINGS MAY CONTAIN 0-2 N ATOMS. THE PREFERRED COMPOUNDS ARE: ETHYL 4- (4-CYANOPHENYL) -6-METHYL-2-OXO-1- [3- (TRIFLUOROMETHYL) PHENYL] -1,2,3,4-TETRAHYDRO-5-PYRIMIDINECARBOXYLATE; (1S) -2-METHOXY-1-METHYL 2-OXOETHYL 4- (4-CYANOPHENYL) -6-METHYL-2-OXO-1- [3- (TRIFLUOROMETHYL) PHENYL] -1,2,3,4-TETRAHYDRO -5-PYRIMIDINE CARBOXYLATE AND ETHYL 6- (BROMOMETHYL) -4- (4-CYANOPHENYL) -2-OXO-1- [3- (TRIFLUOROMETHYL) PHENYL] -1,2,3,4-TETRAHYDRO-5-PYRIMIDINECARBOXYLATE. IT ALSO REFERS TO A USEFUL PHARMACEUTICAL FORMULATION IN THE TREATMENT OF COPD, ACUTE CORONARY SYNDROME, HEART FAILURE DUE TO INIHIBITION OF HUMAN NEUTROPHILIC ELASTASE (ENH)

PE2003000910A 2002-09-10 2003-09-09 INHIBITING HETEROCYCLIC DERIVATIVES OF HUMAN LEUKOCYTIC ELASTASE (HLE) PE20041078A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0220962A GB0220962D0 (en) 2002-09-10 2002-09-10 Heterocyclic derivatives
GB0226609A GB0226609D0 (en) 2002-09-10 2002-11-14 Heterocyclic derivatives
GB0315870A GB2392910A (en) 2002-09-10 2003-07-07 2-Oxopyrimidine derivatives and their use as human leukocyte elastase inhibitors

Publications (1)

Publication Number Publication Date
PE20041078A1 true PE20041078A1 (en) 2005-02-25

Family

ID=39827677

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2003000910A PE20041078A1 (en) 2002-09-10 2003-09-09 INHIBITING HETEROCYCLIC DERIVATIVES OF HUMAN LEUKOCYTIC ELASTASE (HLE)

Country Status (8)

Country Link
JP (1) JP4708034B2 (en)
AR (1) AR042179A1 (en)
EC (1) ECSP055669A (en)
ES (1) ES2414865T3 (en)
GB (1) GB2392910A (en)
PE (1) PE20041078A1 (en)
TW (1) TWI314555B (en)
UA (1) UA82074C2 (en)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA03008714A (en) 2002-09-26 2004-09-10 Oreal Sequenced polymers and cosmetic compositions comprising the same.
EP1565148B1 (en) 2002-09-26 2011-03-30 L'Oréal Glossy liquid composition comprising a sequenced polymer
SE0302486D0 (en) 2003-09-18 2003-09-18 Astrazeneca Ab Novel compounds
FR2860143B1 (en) 2003-09-26 2008-06-27 Oreal COSMETIC COMPOSITION COMPRISING A SEQUENCE POLYMER AND A NON-VOLATILE SILICONE OIL
US8101615B2 (en) * 2004-02-26 2012-01-24 Bayer Pharma Aktiengesellschaft 1,4-diaryl-dihydropyrimidin-2-ones and their use as human neutrophil elastase inhibitors
CA2557272C (en) * 2004-02-26 2012-09-11 Bayer Healthcare Ag Heterocyclic derivatives
TW200808771A (en) 2006-05-08 2008-02-16 Astrazeneca Ab Novel compounds II
TW200808763A (en) 2006-05-08 2008-02-16 Astrazeneca Ab Novel compounds I
FR2904320B1 (en) 2006-07-27 2008-09-05 Oreal POLYMER SEQUENCES, AND PROCESS FOR THEIR PREPARATION
US20110003858A1 (en) * 2006-09-04 2011-01-06 Bergstroem Lena Multimeric heterocyclic compounds useful as neutrophil elastase inhibitors
EA017297B1 (en) 2007-11-06 2012-11-30 Астразенека Аб Some 2-pyrazinone derivatives and their use as inhibitors of neutrophile elastase
EP2234985B1 (en) * 2007-12-20 2012-03-07 Bayer Pharma Aktiengesellschaft 4-(4-cyano-2-thioaryl)dihydropyrimidinones and use thereof
DE102008022521A1 (en) * 2008-05-07 2009-11-12 Bayer Schering Pharma Aktiengesellschaft 1,4-Diaryl-pyrimidopyridazine-2,5-diones and their use
ATE540042T1 (en) * 2008-06-09 2012-01-15 Bayer Pharma AG ANNATED 4-(INDAZOLYL)-1,4-DIHYDROPYRIDINE DERIVATIVES AS C-MET MEDIATORS
TW201036957A (en) 2009-02-20 2010-10-16 Astrazeneca Ab Novel salt 628
DE102009016553A1 (en) * 2009-04-06 2010-10-07 Bayer Schering Pharma Aktiengesellschaft Sulfonamide- and sulfoximine-substituted diaryldihydropyrimidinones and their use
KR20120099639A (en) 2009-10-02 2012-09-11 아스트라제네카 아베 2-pyridone compounds used as inhibitors of neutrophil elastase
US20140221335A1 (en) 2013-02-06 2014-08-07 Boehringer Ingelheim International Gmbh Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
US9115093B2 (en) 2013-03-04 2015-08-25 Boehringer Ingelheim International Gmbh Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
USRE47493E1 (en) 2014-02-20 2019-07-09 Boehringer Ingelheim International Gmbh Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
US9458113B2 (en) 2014-07-31 2016-10-04 Boehringer Ingelheim International Gmbh Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
US9290457B2 (en) * 2014-07-31 2016-03-22 Boehringer Ingelheim International Gmbh Substituted dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
US9440930B2 (en) 2014-07-31 2016-09-13 Boehringer Ingelheim International Gmbh Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
US9657015B2 (en) 2014-07-31 2017-05-23 Boehringer Ingelheim International Gmbh Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
US9475779B2 (en) 2014-07-31 2016-10-25 Boehringer Ingelheim International Gmbh Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity

Also Published As

Publication number Publication date
ECSP055669A (en) 2005-05-30
AR042179A1 (en) 2005-06-15
UA82074C2 (en) 2008-03-11
TW200410963A (en) 2004-07-01
TWI314555B (en) 2009-09-11
HK1088304A1 (en) 2006-11-03
GB2392910A (en) 2004-03-17
JP4708034B2 (en) 2011-06-22
JP2006507355A (en) 2006-03-02
GB0315870D0 (en) 2003-08-13
ES2414865T3 (en) 2013-07-23

Similar Documents

Publication Publication Date Title
PE20041078A1 (en) INHIBITING HETEROCYCLIC DERIVATIVES OF HUMAN LEUKOCYTIC ELASTASE (HLE)
PE20081510A1 (en) DIHYDROPYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS
CO5611147A2 (en) USEFUL NICOTINAMIDE DERIVATIVES AS INHIBITORS P38
PE20060374A1 (en) FUSED HETEROCYCLIC KINASE INHIBITORS
PE20090617A1 (en) AMINO-5 - [- 4- (DIFLUOROMETOXI) PHENYL] -5-PHENYLIMIDAZOLONE COMPOUNDS FOR THE INHIBITION OF -SECRETASE
AR055360A1 (en) MACROCICLIC INHIBITORS OF HEPATITIS C VIRUS
PE20090884A1 (en) INDOL COMPOUNDS AS GLUCOKINASE ACTIVATORS
PE20091466A1 (en) DERIVATIVES OF 4,5-DIHYDRO-OXAZOLE-2-IL-AMINE
PE20090709A1 (en) 5-MEMBER HETEROCYCLIC COMPOUNDS
PE20121282A1 (en) SPIRO-OXINDOL ANTAGONISTS OF MDM2
PE20080404A1 (en) BENZYL-AMINO-PIPERIDINE DERIVATIVES AS CETP INHIBITORS
ATE485044T1 (en) PYRIMIDINE COMPOUNDS AS PURINE RECEPTOR ANTAGONISTS
PE20141827A1 (en) PROTEIN INHIBITORS KINASES
EA200700141A1 (en) NEW AMINO-CYCLIC URINE DERIVATIVES, THEIR RECEIVING AND PHARMACEUTICAL APPLICATION AS KINASE INHIBITORS
AR047056A1 (en) DERIVATIVES OF CONDENSED PYRIMIDINS. PHARMACEUTICAL COMPOSITIONS
PE20050018A1 (en) HETEROAROMATIC PENTACYCLIC COMPOUND AS INHIBITOR OF PROTEIN TYROSINE PHOSPHATASE 1B (PTB1B)
PE20081845A1 (en) NEW AMINOPYRIMIDINE DERIVATIVES AS PLK1 INHIBITORS
AR055144A1 (en) ACID SECRETION INHIBITOR
EA200600315A1 (en) Pyrimidine compounds, their use as a-selective antagonists and a way to obtain them
PE20051141A1 (en) VIRAL POLYMERASE INHIBITORS
PE20060197A1 (en) BICYCLE HETEROCYCLES AS KINASE INHIBITORS
PE20060150A1 (en) SELECTED CGRP ANTAGONISTS, PHARMACEUTICAL COMPOSITIONS AND PROCEDURE FOR THEIR PREPARATION
PE20090160A1 (en) AMINO-5- [4- (DIFLUOROMETOXI) SUBSTITUTE PHENYL] -5-PHENYLIMIDAZOLONE COMPOUNDS AS ß-SECRETASE INHIBITORS
PE20061106A1 (en) DERIVATIVES OF 2- (4-OXO-4H-QUINAZOLIN-3-IL) ACETAMIDE
AR040626A1 (en) USEFUL QUINOLINE DERIVATIVES AS NEUROPEPTIDE RECEIVER AND (NPY)

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed